Powell Lynne 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jan 29, 2019
Insider Transaction Report
Form 4
Powell Lynne
Senior VP - CCO
Transactions
- Exercise/Conversion
Common Stock
2019-01-28$3.22/sh+4,000$12,880→ 4,000 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2019-01-25−6,000→ 85,427 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (6,000 underlying) - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2019-01-28−2,000→ 79,427 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (2,000 underlying) - Sale
Common Stock
2019-01-28$9.91/sh−2,000$19,820→ 0 total - Exercise/Conversion
Common Stock
2019-01-25$3.22/sh+6,000$19,320→ 6,000 total - Sale
Common Stock
2019-01-25$9.60/sh−6,000$57,600→ 0 total - Sale
Common Stock
2019-01-28$9.88/sh−4,000$39,520→ 0 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2019-01-28−4,000→ 81,427 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2019-01-28$3.22/sh+2,000$6,440→ 2,000 total
Footnotes (5)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.
- [F2]The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F4]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018.
- [F5]The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.